Get the Stockscreener App
22.19
3.79%
0.81
After Hours:
22.19
Pacira Biosciences Inc stock is traded at $22.19, with a volume of 1.40M.
It is up +3.79% in the last 24 hours and down -10.67% over the past month.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
See More
Previous Close:
$21.38
Open:
$21.37
24h Volume:
1.40M
Relative Volume:
2.17
Market Cap:
$997.06M
Revenue:
$681.75M
Net Income/Loss:
$70.47M
P/E Ratio:
15.30
EPS:
1.45
Net Cash Flow:
$173.19M
1W Performance:
+4.03%
1M Performance:
-10.67%
6M Performance:
-16.11%
1Y Performance:
+33.92%
1-Day Range:
$21.37
$22.74
1-Week Range:
$20.70
$22.74
52-Week Range:
$16.00
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Name
Pacira Biosciences Inc
Sector
Phone
650-242-8052
Address
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
22.19 | 960.66M | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
144.35 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.42 | 42.46B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.38 | 41.28B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.52 | 23.49B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
438.66 | 19.18B | 3.08B | 1.24B | 1.07B | 25.61 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Upgrade | Truist | Hold → Buy |
| Jan-30-25 | Upgrade | Truist | Sell → Hold |
| Aug-13-24 | Downgrade | Truist | Buy → Sell |
| Aug-12-24 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-12-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-12-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-03-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-07-24 | Resumed | JP Morgan | Overweight |
| Dec-20-23 | Initiated | Raymond James | Outperform |
| Aug-03-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Jan-31-23 | Resumed | Wedbush | Outperform |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jan-03-22 | Resumed | JP Morgan | Overweight |
| Jul-26-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-21-21 | Resumed | JP Morgan | Neutral |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-11-21 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jan-21-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-06-20 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Apr-07-20 | Initiated | Northland Capital | Outperform |
| Mar-20-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Nov-06-19 | Initiated | BTIG Research | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-06-19 | Upgrade | Mizuho | Underperform → Neutral |
| May-02-19 | Upgrade | Stifel | Sell → Hold |
| Feb-01-19 | Downgrade | Mizuho | Neutral → Underperform |
| Aug-06-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Apr-09-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-21-18 | Reiterated | Mizuho | Neutral |
| Feb-16-18 | Downgrade | Needham | Buy → Hold |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Jan-04-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Mkt Perform |
View All
Pacira Biosciences Inc Stock (PCRX) Latest News
Is Pacira BioSciences Inc. stock supported by strong fundamentalsMarket Trend Report & Growth Focused Entry Reports - newser.com
Will Pacira BioSciences Inc. (82P) stock rise with strong economy2025 Retail Activity & Long-Term Safe Investment Plans - newser.com
Why Pacira BioSciences Inc. (82P) stock could outperform next yearJuly 2025 Trade Ideas & Safe Capital Growth Plans - newser.com
Is Pacira BioSciences Inc. stock poised for growthJuly 2025 Big Picture & Accurate Intraday Trading Signals - newser.com
Should I hold or sell Pacira BioSciences Inc. stock in 2025Gap Down & Weekly Market Pulse Alerts - newser.com
Using data tools to time your Pacira BioSciences Inc. exitMarket Volume Report & High Accuracy Trade Signal Alerts - newser.com
How Pacira BioSciences Inc. stock valuations compare to rivals2025 Earnings Surprises & Stepwise Entry and Exit Trade Signals - newser.com
Real time social sentiment graph for Pacira BioSciences Inc.Price Action & Reliable Entry Point Trade Alerts - newser.com
Pacira BioSciences Inc. recovery potential after sell off2025 Growth vs Value & Scalable Portfolio Growth Methods - newser.com
How to integrate Pacira BioSciences Inc. into portfolio analysis toolsTrade Entry Report & Free Verified High Yield Trade Plans - newser.com
What is the fair value estimate for Pacira BioSciences Inc. (82P) stock in 2025Risk Management & Daily Profit Focused Screening - newser.com
Pacira BioSciences Inc. stock retracement – recovery analysisInflation Watch & Real-Time Buy Signal Alerts - newser.com
Can a trend reversal in Pacira BioSciences Inc. lead to recoveryTrade Volume Summary & Weekly Top Gainers Alerts - newser.com
Will Pacira BioSciences Inc. stock keep outperforming rivalsGlobal Markets & High Return Stock Watch Alerts - newser.com
Building trade automation scripts for Pacira BioSciences Inc.Quarterly Portfolio Review & Risk Controlled Daily Plans - newser.com
How Pacira BioSciences Inc. stock trades before earningsMarket Movement Recap & Accurate Entry and Exit Point Alerts - newser.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Connect - ACCESS Newswire
2025-11-02 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Connect | NDAQ:PCRX | Press Release - Stockhouse
Pacira BioSciences, Inc. (PCRX) Stock Forecasts - Yahoo Finance
Pacira BioSciences, Inc. (PCRX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Chart based analysis of Pacira BioSciences Inc. trendsTrade Volume Summary & Growth Focused Stock Reports - newser.com
Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025 - markets.businessinsider.com
Pacira Biosciences, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Trends - Markets Mojo
Pacira BioSciences (PCRX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Pacira BioSciences, Inc. (PCRX) Stock forecasts - Yahoo! Finance UK
Pacira Biosciences Inc Stock (PCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.35%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):